MedTech Innovator

Samay is a developer of an innovative AI-enabled wearable device focused on remote respiratory health management. The company addresses the growing need for effective chronic obstructive pulmonary disease (COPD) diagnostics and management, projected to incur significant healthcare costs in the coming years. Their patented chest patches provide passive monitoring of lung function, achieving 90% accuracy in COPD diagnosis and 83% accuracy in detecting exacerbation biomarkers. The device continuously tracks vital respiratory metrics, including pulmonary volumes, heart rates, and breathing sounds for two weeks, offering users valuable insights to optimize their respiratory health. Additionally, Samay is creating an AI-assisted management platform that supports patients and healthcare providers throughout the care continuum, enhancing personalized care from the comfort of home.

APrevent Medical Inc. is a medical device company founded in 2014 and headquartered in Taipei, Taiwan, with an additional office in Austria. The company specializes in developing therapeutic medical devices aimed at enhancing the quality of life for patients suffering from speech disorders. APrevent Medical focuses on innovative solutions, including a long-term implant system and a speech conversion platform, designed to provide minimally invasive treatments and support for voice and communication issues. By integrating advanced technologies, the company aims to offer effective interventions that enable patients to improve their speech capabilities and overall communication.

SmartCardia SA is a Swiss company, established in 2013 and based in Lausanne, that specializes in the design and development of cardiac monitoring devices and cloud-based AI software. The company focuses on real-time patient monitoring by integrating advanced medical wearable technology with artificial intelligence. SmartCardia has created SmartNeuralNet, a cutting-edge machine learning technology that enhances their medical wearables. These ultra-small devices are designed to continuously track vital bio-signals, including heart rate, breathing rate, and skin conductance, allowing patients to monitor their health effectively. Through a dedicated mobile application, SmartCardia aims to provide actionable insights to individuals with chronic conditions, ultimately empowering them to improve their overall health management.

Nurami Medical Ltd., established in 2014 and based in Haifa, Israel, is a clinical-stage medical device company specializing in the development of innovative solutions for soft tissue repair and regeneration following surgeries. The company's flagship product is a dural substitute patch, designed to replace damaged dura mater during neurosurgeries, promoting enhanced healing and patient recovery. Nurami's technology, based on electrospinning, creates a porous scaffold matrix that facilitates tissue regeneration and incorporates a temperature-sensitive sealant to prevent infections and cerebrospinal fluid leaks. The company aims to address unmet surgical needs and improve patient outcomes across various surgical procedures.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, focused on developing innovative polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company specializes in creating in-situ forming foams designed to deliver local therapy for acute hemorrhage and other critical conditions such as vascular injury and repair. Arsenal Medical has developed two proprietary technology platforms: its therapeutic foam and AxioCore, a novel nanofiber technology that facilitates cell integration and tissue regeneration by enabling controlled delivery of biologics and therapeutics. The company utilizes safe, non-toxic, and biocompatible materials to enhance therapy in complex medical scenarios, positioning itself at the forefront of advancements in local treatment approaches.

SanaHeal is a company focused on developing innovative bioadhesive materials, specifically designed to enhance surgical outcomes. It offers a range of products, including bioadhesive tapes, pastes, and powders, which can effectively bind tissues or organs, serving as alternatives to traditional sutures. These products aim to promote healing while minimizing complications following surgical procedures. SanaHeal's technology is particularly beneficial for patients with multiple traumatic injuries, facilitating improved integration of medical devices with the human body and providing essential care during recovery. Through its advancements in bioadhesive solutions, the company seeks to transform the management of wounds and bleeding in surgical settings.

Solenic Medical, Inc. is a medical device company that focuses on developing a non-invasive treatment for infected metallic implants. Founded in 2019 and based in College Station, Texas, the company employs alternating magnetic fields generated from external coils to eliminate biofilm on the surfaces of these implants. This innovative technology aims to address significant complications that arise from surgeries, including knee and hip replacements, as well as in trauma-related implants such as plates and rods. Solenic Medical's approach offers the potential to replace the costly and risk-laden two-step revision surgical procedure currently used to manage chronic infections in medical implants.

Samay is a developer of an innovative AI-enabled wearable device focused on remote respiratory health management. The company addresses the growing need for effective chronic obstructive pulmonary disease (COPD) diagnostics and management, projected to incur significant healthcare costs in the coming years. Their patented chest patches provide passive monitoring of lung function, achieving 90% accuracy in COPD diagnosis and 83% accuracy in detecting exacerbation biomarkers. The device continuously tracks vital respiratory metrics, including pulmonary volumes, heart rates, and breathing sounds for two weeks, offering users valuable insights to optimize their respiratory health. Additionally, Samay is creating an AI-assisted management platform that supports patients and healthcare providers throughout the care continuum, enhancing personalized care from the comfort of home.

Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

X-BOLT Orthopaedics developed a novel expanding bolt device, with associated implants and instrumentation systems, for internal bone fixation in osteoporotic hip fractures. X-BOLT hip plating and nailing systems allow surgeons choice to treat all morphologies of proximal femoral fractures.

HealthTech Connex is a brain technology company based in the Health and Technology District. It specializes in translational neuroscience innovations aimed at improving neurological performance and overall health outcomes. The company's technology evaluates an individual's cognitive brain health across various conditions, including brain injuries, neurological diseases, and optimization. This enables mental health professionals to detect cognitive impairments related to mental health issues early. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex provides valuable services to care and community sectors globally.

Founded in 2019, Promedius is a company dedicated to transforming the approach to aging through innovative technologies aimed at the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. Promedius has developed PROS® CXR:OSTEO, a pioneering screening solution that utilizes chest X-ray images combined with artificial intelligence to identify individuals at risk for osteoporosis. This technology is designed to prevent severe fractures among the elderly population, facilitating timely intervention and enhancing the overall quality of life. By harnessing AI in medical imaging, Promedius aims to support healthcare professionals in their efforts to improve patient outcomes and extend healthy lifespans.

CytoVeris is a company that specializes in the development of optical-based technologies aimed at assisting surgical oncologists in the identification and removal of tumor tissue during cancer resection surgeries. Founded in 2018 by Alan Kersey in Farmington, Connecticut, the company focuses on enhancing surgeons' ability to achieve clean margins, which is critical for successful cancer treatment. CytoVeris's innovative devices provide real-time assessments of tissue and generate molecular-specific information, producing an optical biomolecular fingerprint for cancer detection. This advanced technology allows for the detection of molecular signatures created by cancer cells, which can lead to improved patient outcomes and reduced healthcare costs by minimizing the need for repeat surgeries.

REMEDI is a solution provider for radiotherapy and radiography.

Nanochon is a medical device company focused on developing innovative solutions for treating cartilage damage in joints. Utilizing 3D printing technology and proprietary nanomaterials, the company aims to create implantable devices that replace lost or damaged cartilage and stimulate new tissue growth. This approach enables healthcare providers to offer cost-effective, on-demand treatments tailored to young and active patients suffering from knee injuries or diseases.

Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.

Flow Medical specializes in the development of multi-function catheters aimed at diagnosing and treating venous thromboembolic illnesses, including pulmonary embolism. The company's innovative platform enhances clot visualization and allows for the targeted delivery of clot-dissolving medication directly to the site of blockage. Additionally, it provides real-time monitoring of treatment progress, enabling clinicians to tailor therapy to the specific needs of each patient. Through its advanced catheter technology, Flow Medical seeks to improve patient outcomes in the management of thrombotic conditions.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Lattice Medical is a French company founded in 2017 that specializes in the design and manufacture of cell regeneration prostheses for women who have undergone mastectomy due to breast cancer. The company addresses the needs of a significant population, as one in eight women is diagnosed with breast cancer, and a substantial percentage undergo mastectomy procedures. Lattice Medical has developed an innovative implantable device called MATTISSE, which facilitates natural breast reconstruction by regenerating autologous adipose tissues. Utilizing advanced technologies such as biomaterials, tissue engineering, and 3D printing, MATTISSE allows for personalized reconstruction in a single surgical procedure. The device is composed of fully biodegradable materials that dissolve post-reconstruction, aiming to replace traditional silicone-based implants. This approach not only enhances the surgical experience by reducing invasiveness and pain but also significantly decreases surgery time, providing health professionals with a valuable tool for restoring patients' bodies and lives.

EndoVision Limited, established in 2018 and headquartered in Hong Kong, specializes in the development of advanced artificial intelligence software aimed at enhancing computer-aided diagnosis in endoscopy. The company's innovative technology integrates AI to improve diagnostic accuracy and efficiency, positioning it as a significant player in the medical technology sector. Through its focus on leveraging artificial intelligence, EndoVision seeks to transform endoscopic procedures and contribute to better patient outcomes in the healthcare industry.

Invicta Medical, Inc. is a medical technology company that specializes in developing innovative therapies for sleep apnea and snoring. Founded in 2013 and headquartered in Portola Valley, California, the company has created a wearable device that utilizes neurostimulation to detect and treat disturbed breathing. This device aims to overcome the limitations of traditional therapies, which are often costly, invasive, and have low compliance rates among patients. By offering a smart, comfortable, and cost-effective solution, Invicta Medical seeks to provide effective treatment options for individuals suffering from sleep disorders.

VinBrain is a healthcare technology company that specializes in artificial intelligence applications within the medical field, particularly in medical imaging and diagnostics. The company offers DrAidTM Teleradiology, a remote medical imaging solution that facilitates the connection of resources and expertise between hospitals, ensuring patients receive quality diagnostic imaging services anytime and anywhere. VinBrain's platform enhances patient outcomes by identifying and distinguishing various types of cancerous cells and tissues, analyzing medical histories to pinpoint potential risk factors, and automatically generating reports based on healthcare data. Utilizing computer vision and generative AI, the company streamlines radiologists' workflows, providing healthcare providers with valuable insights to improve diagnosis, treatment, and overall patient care, while also enhancing operational efficiency.

ATDev specializes in assistive technology and medical device solutions, focusing on the development of innovative mobility devices. These devices are designed to enhance physical therapy services for patients in the United States and around the globe. By integrating robotic technology, ATDev's products aim to reimagine traditional physical therapy, improving accessibility for patients and facilitating better tracking of recovery outcomes. The company's solutions are particularly beneficial for individuals recovering from knee surgery, as they help healthcare providers overcome barriers to treatment and elevate the quality of care offered.

BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

NanoBioFAB is a company based in Frederick, Maryland, specializing in the development of wearable, smart healthcare and medical devices utilizing nanotechnology. Founded in 2015, the company produces innovative products such as iNose, a device that allows individuals to detect, track, and monitor their body’s skin vapor-print. This device connects wirelessly to mobile phones, enabling users to track their fat burning rate, assess the effectiveness of their exercise routines, and observe the long-term effects of their dietary choices on metabolic rates. Additionally, NanoBioFAB offers nanoprinting technology and artificial intelligence sensors aimed at enhancing telemedicine and personalized healthcare solutions. The company is dedicated to making advanced healthcare accessible and affordable for both people and pets.

Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices aimed at addressing challenges in infectious disease testing, particularly for influenza. The company manufactures microchip-based devices that allow users to quickly and accurately diagnose illnesses. By providing early diagnosis solutions, Nanotis supports medical professionals in practical healthcare settings, thereby enhancing the efficiency of healthcare delivery and improving patient outcomes.

Aurie is a medical device company founded in 2018 and headquartered in New York, United States. The company specializes in developing a reusable urinary catheterization system aimed at empowering individuals with disabilities. Aurie's innovative system is designed to provide convenient, discreet, and hygienic options for catheterization, significantly reducing the risk of infection. By enhancing user confidence and control, Aurie's product enables individuals to manage their condition more effectively, fostering greater independence and the ability to lead active, fulfilling lives.

Craif Inc., formerly known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for the early detection of cancer through non-invasive urine tests. The company focuses on utilizing MicroRNA, an early cancer biomarker, which facilitates the identification of cancer at its initial stages, thereby significantly increasing survival rates and improving patient prognosis. Craif aims to address the challenges of traditional cancer diagnosis methods, which can be painful and often lack the necessary accuracy for early detection. By leveraging exosome-based liquid biopsy tests and ribonucleic acid technology, Craif provides research institutions with high sensitivity and specificity in distinguishing between cancerous and non-cancerous samples, positioning itself as a pioneer in the field of early cancer diagnosis.

TYBR Health is a medical device company founded in 2020 by Tim Keane and Alex Smith in Houston, Texas. The company specializes in the development of a sprayable hydrogel designed to protect healing tissues and limit internal scarring, a common complication following surgery. This naturally derived solution has demonstrated a 75% reduction in scarring in preclinical studies. The hydrogel is delivered through a simple, steerable device, making it suitable for both open and minimally invasive surgical procedures. By reducing adhesions and enhancing tissue healing responses, TYBR Health aims to improve patient recovery outcomes and minimize the risk of damage to vital internal organs during surgical operations.

INIA Biosciences is a developer of innovative medical devices that leverage sound wave technology to create non-invasive, home-administered systems for managing chronic inflammatory diseases. The company focuses on a closed-loop monitoring system designed to treat and prevent organ failure by integrating biomarker monitoring with an ultrasound stimulator. This approach aims to reduce inflammation linked to transplant rejection rates and minimize reliance on immunosuppressant drugs. By providing novel diagnostic sensing capabilities, INIA Biosciences enables physicians to better manage chronic diseases and improve patient outcomes.

Butterfly Medical Ltd is a medical-device company founded in 2014 and based in Yokne'am, Israel. It specializes in the development of an implantable device aimed at treating Benign Prostatic Hyperplasia (BPH), a condition commonly referred to as enlarged prostate. The company's innovative device provides a fast, simple, and minimally invasive alternative to conventional BPH treatments, including medications and surgery. It can be implanted in under ten minutes in an office setting using local anesthesia, without the need for surgical incisions or removal of prostate tissue. This approach not only minimizes side effects but also eliminates the requirement for hospitalization or general anesthesia. Initial clinical trials have shown promising results, with effective outcomes in opening blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies in leading medical centers across Europe to validate its device's efficacy and safety.

Fasciotens GmbH is a medical technology company based in Essen, Germany, that specializes in developing innovative devices for open abdomen therapy. Founded in 2016, the company addresses critical conditions such as severe infections, postoperative complications, and injuries that necessitate leaving the abdomen open. Their unique approach involves maintaining tension in the abdominal wall while increasing intra-abdominal volume, which is essential for effective treatment. This method combines the principles of mesh-mediated traction with the concept of an external fixator, ultimately enhancing the chances of survival for critically ill patients facing abdominal compartment syndrome and other serious medical challenges.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Surgical Automations specializes in the development of surgical robots and automation technologies aimed at improving patient safety and reducing medical errors. The company offers an AI-based autonomous robotic navigation system tailored for endoscopic diagnostic and interventional procedures. Their innovative approach includes an automated endotracheal intubation system that accurately detects the trachea's opening and facilitates the insertion of the endotracheal tube. This technology significantly enhances the precision of surgical procedures, enabling medical professionals to minimize risks and improve outcomes during operations.

Ortho-tag is a developer of innovative in-vivo platforms that facilitate the connection between digital health applications and implanted biosensors within the human body. The company's technologies focus on enhancing wireless communication with medical devices through proprietary transcutaneous volume conduction. This enables real-time data exchange, in-vivo storage, and the integration of nanodiagnostic and therapeutic functions in smart medical implants. By providing a comprehensive system for wireless communication and data management, Ortho-tag supports medical device developers in advancing the capabilities of healthcare technology.

FemTherapeutics Inc. is a Montreal-based medical device company focused on personalizing therapeutics in women’s health. The company has developed an artificial intelligence platform that utilizes patient data and three-dimensional printing technology to create customizable gynecological prosthetics, specifically designed for the management of Pelvic Floor Disorders. Their innovative approach aims to improve the clinical outcomes for women suffering from conditions such as pelvic organ prolapse and stress urinary incontinence, providing non-invasive solutions that enhance quality of life through effective symptom relief. FemTherapeutics’ commitment to leveraging advanced technology positions it at the forefront of women's health innovation.

The Shape Sensing Company specializes in advanced fiber optic 3D guidance technology that enables physicians to navigate medical devices within patient-specific anatomical models. Primarily focused on enhancing endovascular procedures, the company's innovative platform allows vascular surgeons and interventional radiologists to efficiently conduct approximately 2.8 million procedures annually in the United States, utilizing a proprietary 3D guidance workstation and guidewire. This technology not only aims to reduce procedure times and operational costs but also enhances patient outcomes by eliminating reliance on traditional X-ray imaging. Beyond its initial applications in medicine, The Shape Sensing Company is also poised to expand its impact across multiple industries, including aerospace, civil engineering, mining, and energy, through collaborations with various Original Equipment Manufacturer (OEM) partners developing 3D-guided devices.

CancerFree Biotech is a start-up focused on personalized cancer treatment through advanced technology. The company specializes in analyzing circulating tumor cells (CTCs) to create organoid systems, which assist healthcare professionals in developing tailored treatment strategies for patients at all stages of cancer. By utilizing its proprietary E.V.A. technology platform, CancerFree Biotech combines organoid culture systems with artificial intelligence for rapid expansion of CTCs into cancer-derived organoids (CDOs). This innovative approach supports various applications in cancer research, including cell therapy, cancer vaccines, and new drug development. The aim is to reduce ineffective drug use and alleviate the burden of frequent testing on patients during their treatment journey, ultimately enhancing the effectiveness of therapeutic interventions.

Dopl Technologies, co-founded by an ex-Microsoft engineer and two Harvard-trained specialists, is dedicated to enhancing healthcare accessibility for underserved populations, particularly in rural areas. Recognizing the disparity in healthcare access, where specialists are predominantly located in urban centers, Dopl has developed a telerobotic ultrasound system. This innovative platform allows specialists to conduct diagnostic ultrasound procedures remotely, thus enabling patients in distant locations to receive timely and effective care. By leveraging this technology, Dopl aims to improve patient outcomes while also benefiting hospitals through increased revenue and reduced operational costs. The company’s mission focuses on ensuring that quality healthcare is available to all individuals, regardless of their geographical location.

DiaMonTech AG is a Berlin-based medical technology company founded in 2015, specializing in the design, development, and commercialization of non-invasive blood glucose monitoring devices. Utilizing proprietary laser-based photo-thermal detection technology, DiaMonTech offers solutions that allow diabetes patients to measure their glucose levels without the pain of finger pricking or the need for blood samples. The company has developed several innovative products, including D-BASE, a shoebox-sized device for conducting human trials, D-pocket, a portable device for frequent glucose level tracking, and D-BAND, a wearable device that continuously monitors blood glucose levels. Through these advancements, DiaMonTech aims to improve the quality of life for individuals managing diabetes.

NIRAMAI Health Analytix Private Limited is a Bengaluru-based company that specializes in cancer screening through its innovative software, Thermalytix, which leverages machine intelligence to analyze thermography images. Founded in 2016, the company offers a range of hardware-software solutions tailored for various users, including a compact screening device for specialty hospitals, a handheld device for independent medical practitioners, and a portable solution designed for large-scale screenings. NIRAMAI's technology enables early detection of breast cancer, identifying tumors significantly smaller than those detectable by traditional methods. Their approach is non-contact, painless, and free of radiation, making it a low-cost and accessible option for women of all age groups to undergo frequent screenings without adverse effects. By facilitating early diagnosis, NIRAMAI aims to improve survival rates and enhance the quality of cancer care.

KA Imaging Inc., founded in 2015 and based in Waterloo, Canada, specializes in designing and manufacturing advanced X-ray detectors for both medical and non-medical applications. The company's portfolio includes static X-ray detectors for identifying faults in pipes, dual-energy detectors for baggage screening at airports, dynamic detectors for inspecting engines with moving parts, and mammography detectors. Notably, KA Imaging has developed the world's first portable dual energy subtraction X-ray detector, which uses clinically proven technology to enhance sensitivity in detecting diseases such as pneumonia, nodules, fractures, and verifying catheter positions. This device, known as Reveal, has received FDA 510(k) clearance and is sold globally. The company employs a team of 20 full-time and 10 part-time/contract employees and holds 52 global patents and 17 issued US patents.

INOPASE is a medical device company focused on the development of wirelessly powered, closed-loop implantable neuromodulation technologies. The company is currently working on closed-loop sacral neuromodulation systems for the treatment of overactive bladder and closed-loop brain neuromodulation systems aimed at addressing epilepsy. INOPASE's platform utilizes advanced algorithms to enable personalized treatment plans, detecting symptoms and providing targeted stimulation therapy to patients with chronic neurological diseases.

AccurKardia is an ECG-led diagnostics software company dedicated to enhancing the utility of ECG data as a diagnostic tool and biomarker to improve patient outcomes globally. The company specializes in cloud-based diagnostic solutions, including AccurECG™, an FDA-cleared software that provides fully automated, near real-time ECG interpretation. Additionally, AccurKardia developed AK+ Guard™, an AI-driven solution designed to detect hyperkalemia using Lead I ECG data, which aids patients with chronic kidney disease and end-stage renal disease in identifying dangerously high potassium levels at an earlier stage; this product has received FDA Breakthrough Device Designation. The company's aortic stenosis detection model, AK-AVS™, also received similar recognition. AccurKardia participated in the 2024 Cohort of MedTech Innovator and was selected for the inaugural American Heart Association's Heart and Brain Health Accelerator track, further emphasizing its commitment to advancing cardiac diagnostics and monitoring.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Qritive is a technology company that offers an artificial intelligence-powered diagnostic platform aimed at enhancing the accuracy and efficiency of cancer diagnoses. By utilizing advanced AI and natural language processing, Qritive's solution enables medical professionals to analyze microscopy images alongside patients' medical histories. This innovative approach allows hospitals to streamline their diagnostic processes, ultimately reducing costs and improving patient outcomes. With the rising incidence of cancer, Qritive addresses a critical need in the healthcare sector, equipping doctors with modern tools to aid in timely and precise cancer detection.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

FibriCheck is a medically certified application designed for the screening and monitoring of irregular heart rhythms, including atrial fibrillation. Functioning as a software-only solution, it allows users to measure their cardiac rhythm simply by placing a finger on their smartphone camera, making it accessible for use anytime and anywhere. The application automatically shares the collected data with medical professionals, facilitating quicker diagnoses and the development of appropriate treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, enabling it to leverage everyday smartphones and wearables. This innovative approach aims to enhance cardiovascular care by accurately detecting and tracking heart rhythm issues, while also helping individuals manage conditions such as high blood pressure and heart failure through user-friendly tools and customizable health plans.

iCE Neurosystems is a developer of an advanced neuromonitoring platform aimed at enhancing the diagnosis and treatment of brain injuries. The company combines innovative devices, cutting-edge software, and big-data analytics to deliver real-time insights into brain health. This integration enables healthcare professionals to receive early warnings and guide treatment for patients suffering from brain injuries, particularly in critical care settings. By providing revolutionary insights, iCE Neurosystems enhances the ability of doctors and nurses to diagnose and prevent brain injuries more effectively.

Ligence is a Deep Tech startup based in Lithuania, founded by a team of medical doctors with expertise in artificial intelligence. The company focuses on developing innovative solutions for healthcare, particularly in the field of cardiology. Its flagship product, Ligence Heart, automates the analysis of heart ultrasound images using advanced deep learning algorithms. This technology is designed to recognize various heart image views and perform necessary measurements automatically, allowing medical professionals to bypass manual calculations. By streamlining the analysis process, Ligence Heart enhances the efficiency of cardiac ultrasound assessments, enabling cardiologists and sonographers to devote more time to patient care and significantly reduce analysis time.

Prevencio is a biotechnology company focused on developing innovative multi-proteomic biomarkers aimed at transforming blood tests for cardiovascular disease. Utilizing artificial intelligence, the company's biomarkers analyze established clinical data sets to create novel, multi-protein tests that are algorithmically scored. These tests enable clinicians to evaluate the effects of medications before and after administration, specifically concerning a composite risk of heart attack, stroke, and cardiac death. By leveraging advanced technology in biomarker development, Prevencio seeks to enhance the accuracy and effectiveness of cardiovascular diagnostics.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at addressing pelvic health conditions. The company develops micro-implants that deliver targeted treatment by stimulating specific nerves, allowing for local modulation of innervation to muscles and organs. This innovative approach enables the provision of less invasive, safer, and more effective therapies for various conditions, including incontinence, sexual dysfunction, and chronic pain. By concentrating on precision treatment, Juniper Biomedical seeks to improve patient outcomes and enhance quality of life for individuals suffering from these health issues.

Neurovalens is a UK-based company founded in 2013 that specializes in developing medical devices grounded in neuroscience, bioscience, and neurophysiology. The company's portfolio includes Stimu Slim and Modius, electronic headsets designed to address obesity through non-invasive neurostimulation. Neurovalens' technology focuses on transdermal activation of key brain regions to modulate autonomic function, circadian rhythms, and metabolic processes, offering healthcare providers drug-free treatment options for various health conditions. The company has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme to enhance its research and development activities.

Artificial intelligence driven software applications for digital health technologies. We train multimodal systems to be able to execute automated administration optimisation tasks as well as repetitive patient monitoring and classification solutions. We work closely with the NHS.

IFPx is a company focused on developing innovative monitoring technology for patients with chronic illnesses, beginning with heart failure. The company has created a patient monitoring device that directly analyzes fluid buildup, which is crucial for managing such conditions. By utilizing interstitial fluid pressure sensors, IFPx aims to enhance the monitoring capabilities available to healthcare professionals, thereby improving patient outcomes in heart failure management. The company's technology represents a significant advancement in the approach to chronic illness treatment, emphasizing the importance of real-time data in patient care.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.

Fingy3D is a company focused on making prosthetic devices accessible to all, specifically targeting the need for finger prosthetics. Utilizing an AI scanner, Fingy3D measures the dimensions of an individual's finger to create a custom-fit prosthetic. This innovative approach allows customers to receive 3D-printed prosthetic fingers conveniently at their doorsteps, enhancing the quality of life for those in need of such devices.

Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.

Biotome is a biotechnology research firm focused on developing advanced antibody diagnostic tests. The company specializes in identifying markers that indicate a high risk of stomach cancer, aiming to provide more precise and detailed disease information compared to current screening methods. By leveraging next-generation technology and precision immunology, Biotome's tests are designed to enhance the ability of medical professionals to treat patients effectively.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Xcision Medical Systems, LLC is a medical technology company focused on developing innovative stereotactic radiotherapy solutions aimed at enhancing cancer treatment. The company specializes in manufacturing radiosurgery devices specifically designed for breast cancer treatment. Its technology utilizes stereotactic gamma irradiation, allowing for a complete course of radiation therapy to be delivered in a single, noninvasive session. This approach significantly reduces the duration of treatment compared to traditional methods, while minimizing radiation exposure to surrounding healthy tissues, including the lungs and heart. As a result, patients can resume their daily activities more quickly and with less discomfort, ultimately improving their quality of life. Additionally, Xcision's advancements enable healthcare professionals to enhance the overall quality of cancer care they provide.

PanTher Therapeutics, Inc. is a biotechnology company focused on developing innovative drug-delivery treatments for cancer. Founded in 2014 and based in Cambridge, Massachusetts, the company has created a proprietary platform that enhances therapeutic responses while minimizing side effects. This technology allows for direct and sustained delivery of drugs to tumor sites, thereby improving the efficacy of treatment and reducing the toxicity often associated with traditional intravenous or oral administration methods. PanTher's distinctive targeting capability positions it to address some of the most challenging cancer types, with a lead investigational candidate aimed at treating pancreatic cancer.

Neurava is a healthcare company focused on improving the lives of epilepsy patients through the development of non-invasive wearable diagnostic devices. These devices monitor critical biological signals associated with epilepsy and the risk of sudden unexpected death in epilepsy (SUDEP), offering a reliable solution for both patients and their caregivers. By providing accurate and timely alerts, especially during nighttime, Neurava's technology empowers caregivers to respond quickly and take preventive actions, thereby enhancing patient safety and peace of mind. The company's commitment to advancing medical device manufacturing and health diagnostics highlights its role in addressing the challenges faced by those with uncontrolled epilepsy.

Perceptive Medical is a developer of advanced medical devices aimed at enhancing blood pressure management in critical care settings, such as the intensive care unit (ICU) and operating room. The company's products are designed to integrate seamlessly into modern clinical workflows, providing healthcare providers with precise tools to address inefficiencies in patient care. By focusing on delivering measurable improvements in blood pressure therapy, Perceptive Medical plays a vital role in optimizing patient outcomes and supporting clinical professionals in their efforts to enhance overall care efficiency.

Xtremedy Medical, based at NUI Galway, specializes in manufacturing innovative surgical devices. These devices use electrical signals to treat bone and deep tissue infections, including diabetic foot ulcers. By targeting both surface and underlying infections, the company's technology helps doctors enhance treatment outcomes, reducing the risk of amputations and promoting faster patient recovery.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

ImmersiveTouch Inc., established in Chicago, Illinois in 2005, specializes in developing, installing, and managing virtual reality simulators for medical training and patient engagement. The company's core offering is a high-fidelity immersive surgical simulator, housed within an 'immersive pod', which enables surgeons to interact with realistic 3D computer-generated anatomical models using haptic instrument replicas. This system provides lifelike visual, tactile, and audio sensations, facilitating skill development and pre-operative planning across various medical specialties such as core surgery skills, neurological surgery, spine, and ophthalmology. Additionally, ImmersiveTouch has expanded its offerings to include AI-driven digital surgery platforms, the Ikshana XR platform, which provides clinicians with data insights to enhance decision-making, improve patient outcomes, and optimize surgical resource allocation.

Covellus is a medical device company focused on developing innovative platform technology for catheters used in minimally invasive surgeries. The company specializes in manufacturing vascular catheter devices and modular catheter systems, which allow physicians to customize existing devices to meet the specific needs of individual patients. By enhancing the versatility and adaptability of medical devices, Covellus aims to improve treatment outcomes in various medical procedures.

Endocision is a medical device company focused on creating innovative minimally-invasive technologies for the diagnosis and treatment of lung diseases. The company specializes in robotic bronchoscopy technologies and a cryo-biopsy platform, which enhance the safety and effectiveness of procedures used by healthcare professionals. Endocision's solutions aim to facilitate the diagnosis and management of conditions such as interstitial lung disease and lung cancer, thereby improving patient outcomes through advanced medical interventions.

Universal Brain is a company dedicated to advancing mental health treatment through innovative neurofeedback systems that leverage physiological data. It specializes in the research and development of advanced treatment algorithms powered by deep learning, which integrate magnetic resonance imaging and electroencephalogram data. Additionally, the company designs and manufactures portable electroencephalograph headsets that facilitate the application of its neurofeedback therapies. By providing health professionals with enhanced insights into brain data analysis, Universal Brain aims to improve psychiatric treatment outcomes and individualize mental health care.

Happitech is a pioneering company that offers a CE Certified heart rate software development kit (SDK) for Android and iOS, specifically designed for remote patient management applications. The company's innovative algorithms enable medical-grade vital signs monitoring directly through a smartphone, utilizing only the device's camera and PPG technology. This integration facilitates the collection of critical health data, allowing healthcare providers, wellness practitioners, and patients to monitor conditions such as Atrial Fibrillation, heart rate, and heart rate variability. Happitech's technology finds applications in various domains, including telemedicine, population health management, and personal health programs, while supporting initiatives in stroke prevention and cardiac arrhythmia detection. The company has received multiple accolades, including recognition as one of the top Dutch COVID-19 healthcare companies and awards for its disruptive innovations within the health sector.

Adcura Inc., established in 2013, is a specialized medical device company dedicated to enhancing spine surgery outcomes through innovative, minimally invasive solutions. The company's portfolio comprises retractors, disposable accessories, and adjustable lumbar fusion devices, all designed to improve surgical efficiency and reduce post-operative complications for patients with spine-related issues. Adcura achieves this by focusing on precision technologies and advanced surgical techniques tailored to each patient's specific needs.

Sonavi Labs, Inc. is a medical device and software company based in Baltimore, Maryland, founded in 2017. The company specializes in developing advanced technologies that analyze body sounds to aid in the diagnosis of respiratory diseases. By utilizing artificial intelligence, Sonavi Labs creates innovative products that enhance the capabilities of healthcare providers and improve patient experiences. Its devices are designed to detect and manage respiratory conditions by listening to bodily sounds and identifying abnormalities, thereby enabling healthcare professionals to monitor, diagnose, and potentially predict diseases effectively. Through its focus on modern medical solutions, Sonavi Labs aims to transform the landscape of respiratory health monitoring.

Hypervision Surgical is a company focused on enhancing surgical precision, safety, and efficiency through advanced imaging technology. It has developed a non-contact and non-invasive optical imaging system that utilizes hyperspectral imaging to analyze tissue in real-time. By splitting light into multiple spectral bands, the system enables clinicians to visualize and characterize tissues during surgery without the need for contrast agents, thereby reducing patient risk. This AI-powered solution facilitates advanced computer-assisted tissue analysis, equipping surgeons with critical data that supports informed decision-making during procedures. Hypervision Surgical aims to transform the landscape of surgery by guiding clinicians with innovative imaging solutions that prioritize patient safety and operational effectiveness.

Senseye, Inc. is a Los Angeles-based company founded in 2015 that specializes in developing innovative smart contact lenses capable of non-invasively recording and analyzing information from users. These contact lenses are designed to infer human emotions, thoughts, and health states, thereby assisting in various applications such as market research, disease diagnosis, and early detection of medical conditions like strokes and heart attacks. By utilizing novel measurements of ocular physiology, Senseye aims to quantify cognitive abilities and psychological well-being, providing valuable insights into vital signs, attention, cognitive load, and fatigue. The company is committed to advancing technology that enhances emotional responses and mental health diagnostics, enabling clinicians to offer personalized care and effectively track patient outcomes over time.

Averto Medical specializes in the manufacture of innovative medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their primary product focuses on facilitating minimally invasive colorectal tumor removal, aiming to replace multiple surgical procedures and reduce associated complications.

Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. It specializes in the development of advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and various materials. The company offers a multi-modal coherent Raman scattering microscope aimed at research and development as well as medical applications. Invenio Imaging's innovative platform technology is designed to facilitate intraoperative histology by providing high-resolution imaging that allows for the examination of specimens from multiple sites within a surgical cavity. The company was established based on research conducted by Professor Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.

Knowtex is a technology company that specializes in enhancing administrative efficiency within the healthcare sector. By leveraging artificial intelligence and voice technology, it captures and analyzes conversations between healthcare providers and patients to extract relevant medical information. This process allows Knowtex to generate detailed visit notes that include billing code suggestions and facilitate order entry. The platform aims to reduce the administrative burden on healthcare professionals, ensuring that visits are billed accurately and efficiently. Additionally, Knowtex fosters personable interactions with patients, contributing to improved overall care experiences. For further inquiries, the company provides an online inquiry form on its website.

Fingy3D is a company focused on making prosthetic devices accessible to all, specifically targeting the need for finger prosthetics. Utilizing an AI scanner, Fingy3D measures the dimensions of an individual's finger to create a custom-fit prosthetic. This innovative approach allows customers to receive 3D-printed prosthetic fingers conveniently at their doorsteps, enhancing the quality of life for those in need of such devices.

NeuraStasis is focused on developing a non-invasive electrical neurostimulation method aimed at preventing strokes. The company's innovative device is designed to activate the body's natural oxygen-preserving and anti-inflammatory reflexes, which helps to protect brain tissue during critical moments. By preserving brain function, NeuraStasis enables patients to leave the hospital without disabilities, offering healthcare providers additional time to intervene effectively. This approach not only enhances patient outcomes but also represents a significant advancement in stroke treatment technology.

MACH32 is a medical device company focused on developing innovative drug delivery solutions to address longstanding health challenges. The company designs medical devices that facilitate effective pre-hospital treatment of trauma, including advanced drug-delivery systems. These technologies are specifically engineered to enhance the safety and efficiency of healthcare professionals, allowing them to protect themselves from infectious aerosols, particularly during critical situations such as the Covid-19 pandemic. MACH32 aims to provide safe, reliable, and functional tools that can save lives in urgent healthcare scenarios.

270Surgical Ltd. is a medical device company based in Netanya, Israel, founded in 2016. The company specializes in developing innovative surgical technologies, notably its flagship product, the SurroundScope System. This pioneering laparoscopic camera system features 270-degree wide field of view technology, which significantly enhances visualization during surgeries, thereby reducing the risk of 'off-screen' injuries and improving patient outcomes. The SurroundScope is designed to address common challenges faced in laparoscopic procedures, such as restricted visibility, lens fogging, and obstructions caused by surgical smoke. The system has received FDA clearance and is endorsed by prominent leaders in the field, establishing its credibility and effectiveness in enhancing surgical safety and efficiency.

Pumpinheart is a medical device company specializing in the development of an implantable left ventricular assist device (LVAD) for the treatment of heart failure with preserved ejection fraction (HFpEF). Their device, an electromedical pump, is designed to reduce left atrial pressure during diastole, improving heart function and potentially reducing hospitalizations. The pump is implanted in the left ventricle and operates in sync with the heart's natural rhythm, providing a minimally invasive treatment option for patients with HFpEF.

Purgo Scientific is a medical device company focused on developing innovative solutions for targeted therapeutic drug delivery. The firm is working on a localized drug delivery device aimed at addressing the critical issue of biofilm infections in orthopedic surgery. This technology is designed to treat and prevent surgical site infections that can arise from the presence of indwelling orthopedic implants. By enabling precise medicine delivery, Purgo Scientific's device not only seeks to eradicate infections caused by biofilms but also has potential applications in managing pain and oncology-related health issues.

AMI Co., Ltd is a Japanese company based in Minamata-shi, established in 2015, that specializes in the manufacturing of medical equipment, primarily stethoscopes. In addition to producing medical devices, AMI is involved in healthcare consulting, offering services such as hospital management and clinical research. The company is also focused on developing telehealth solutions, including a telemedicine system that enhances remote medical consultations. Among its innovations is a video chat platform designed for remote auscultation, which allows for the separate transmission of heart sounds as both audible and visible data, thereby improving patient access to medical services through telemedicine initiatives.

VeinWay is a medical device company focused on developing innovative solutions for the treatment of chronic venous occlusions caused by blockage or disease. The firm's primary offering is a specialized catheter designed to recanalize obstructed veins, providing physicians with a dedicated tool to navigate and clear complicated blockages. By facilitating the restoration of blood flow to the heart, VeinWay aims to transform the management of chronic venous disease and improve patient outcomes. The company's technology not only enables medical professionals to cross previously un-crossable obstructions but also aims to reduce the time required for such procedures.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

JuneBrain, LLC is a biotechnology company focused on enhancing the management of multiple sclerosis through innovative technology. Founded in 2017 and headquartered in Washington, D.C., the company is developing a wearable, non-invasive imaging device that allows patients to monitor their disease activity from the comfort of their homes. This device is designed to facilitate the early detection of multiple sclerosis attacks and improve the monitoring of treatment efficacy. By leveraging telemedicine, JuneBrain aims to optimize remote assessments of neurological conditions, with the long-term objective of expanding its technology to address a wider range of neurodegenerative diseases. The company's approach is intended to enable more frequent and accessible monitoring of brain health, thereby enhancing patient care.

Manufacturers of innovative medical devices intended to incorporate sensors, both therapeutic and diagnostic, to help people overcome musculoskeletal problems. The company provides NMES (Neuromuscular Electrical Stimulation) devices that invoke neuroplasticity for optimal outcomes and offers medical devices for physical therapy and rehabilitation, thereby enabling patients to regain and improve their range of motion and function.

Nininger Medical is a medical technology company focused on developing innovative solutions for heart failure treatment. The company is currently working on a transcatheter tricuspid valve replacement device (TTVR) that utilizes proprietary 3D thin film technology. This advanced approach aims to provide effective heart valve therapies, helping to prevent structural heart failure in patients. Nininger Medical has gained recognition for its innovative efforts, recently receiving a Small Business Innovation Research grant from the National Science Foundation, which underscores its commitment to advancing healthcare solutions.

Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.

Thermidas, a Finnish health technology company, specializes in developing and advancing infrared thermal imaging for diagnostic purposes. Its core product is thermal imaging software, designed to support screening, early diagnostics, and evaluation of treatment effectiveness. The technology enables swift and simple detection of asymmetric body temperature, which can indicate underlying health issues like inflammation, circulatory problems, and potential ulcers. This allows university hospitals and experienced clinicians to identify and diagnose conditions at earlier stages than traditional methods.

CerebraAI is a digital diagnostic company focused on advancing stroke diagnosis through the application of artificial intelligence. Established in 2018, the company has developed its CEREBRA software, which utilizes deep learning algorithms to enhance the efficiency of CT machines. This technology enables the rapid detection of acute ischemic stroke within five minutes using non-contrast computed tomography. By providing community hospitals with tools for faster and more accurate diagnosis, CerebraAI aims to improve outcomes for neuroradiology and stroke patients during critical treatment windows.

CardieX Limited is a global health technology company specializing in cardiovascular health management. Founded in 1994 and headquartered in Sydney, Australia, the company designs, manufactures, and markets medical devices aimed at measuring patient risk for hypertension, cardiovascular disease, and other vascular disorders. Its product offerings include devices that utilize patented SphygmoCor technology to assess arterial stiffness and central blood pressure waveforms. Additionally, CardieX develops the Arty platform, which provides physiological and health analytics for wearable devices. The company also offers TeleHealth Services, connecting patients with health coaches through digital and mobile tools. CardieX's solutions are provided to hospitals, clinics, research institutions, and pharmaceutical companies globally. The company has strategic partnerships, including a collaboration with Blumio Inc. for developing wearable sensors and a joint development agreement with inHealth for hypertension and cardiovascular programs. CardieX was previously known as AtCor Medical Holdings Limited until its name change in June 2018.